

Global Viral Vector Manufacturing Market Size study, by Type (Adenoviral, Retroviral, Adeno-Associated, others), by Application (Vaccinology, Gene Therapy), by Disease (Genetic Disorders, Infectious Diseases, Cancers, Others), End-User (Research Institutes, Biopharmaceutical & Pharmaceutical Companies, Others) and Regional Forecasts 2018-2025

https://marketpublishers.com/r/G78D9F82E25EN.html

Date: May 2019

Pages: 200

Price: US\$ 2,568.00 (Single User License)

ID: G78D9F82E25EN

Abstracts

Global viral vector manufacturing market is valued approximately USD 226.21 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 24.3% over the forecast period 2018-2025. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells. The market growth is primarily attributed to the availability of funding for the advancement of gene therapy, and increasing prevalence of cancer, genetic disorders & infectious diseases. However, the market growth is restricted by the high risk of undesirable outcomes. The significant developments in Gene therapy to cure rare diseases such as cancer, chronic diseases and also some genetic disorders, are leading the increasing number of clinical trials. High number of active clinical trials to access the safety of viral vector vaccine in the North America region has also provided a major impetus to the viral vector vaccine manufacturing market. For instance, as of 2016, a clinical study named Dose-Ranging trial of safety & immunogenicity of an oral adenoviral-vector based RSV vaccines is going-on in Optimal Research Melbourne, Florida (United States), in order to detect respiratory syncytial virus (RSV). On March 2017, as per the official website of the company named American Gene Technologies International Inc (United States), has collaborated with Geo Vax Labs Inc to conduct a Phase 1 clinical trial investing AGT's viral vector vaccines to cure HIV infection. Viral vector-based vaccines are considered one of the most promising candidates for vaccine development, hence growing R&D



expenditure for the development of new medicines in North America presents a huge opportunity for the growth of viral vector vaccine manufacturing market. Global Viral Vector Manufacturing Market is segmented based on Type, Disease, Application, and Industry. Based on the type of disease, the global viral vector market is segmented into Genetic disorders, infectious disease, cancers and others. Currently the market is dominated by Cancer disease with 46.75% revenue share in 2017. On the basis of type the global viral vector manufacturing market is segmented into Adenoviral, Retroviral, Adeno-associated viral and others. Among these retroviral holds the largest revenue share of 32.37% in 2017. Viral vectors are promising tools for gene therapy and vaccines. The viral vector vaccine segment was anticipated to dominate the revenue share in 2015 with 53.43% revenue share in 2015. However, gene therapy segment is anticipated to surpass the global revenue share in 2018. Furthermore, owing to the growing demand for phase III and commercial manufacturing support, the bio pharma companies are making significant investment in capacity and technologies designed to support the manufacture of viral vectors. The number of clinical trials has seen a notable increase in past few years and is anticipated to grow further over the forecast period. The comping years are anticipated to witness the development of strong pipeline of molecules. This trend will fuel the significant opportunities in the global viral vector market.

The regional paradigm of the global viral vector manufacturing market is divided into North America, Europe, Asia Pacific, Latin America, and Rest of the world. Global market revenue is dominated by North America region with 47.73% revenue share in 2017. The primary factors supporting the market dominance in the region are the strong presence of major viral vector manufacturers, higher investment on Research & Development both from research institutes and private organizations and increasing prevalence of related diseases such as cancer, infectious diseases and others. However, the Asia Pacific region is anticipated to pose significant opportunities for the viral vector manufacturing market in coming years. The region is anticipated to grow at the highest CAGR of 26.7% over the forecast period. The region is anticipated to witness an increase in pipeline molecules in coming years. Further, there will be significant change in the regional completive landscape in the APAC region owing to the upcoming acquisition of regional biopharma companies and research laboratories by big companies.

Market player included in this report are: Wuxi Apptec CGT Catapult Lonza



UniQure
Merck
Cobra Biologics
Oxford BioMedica
Fujifilm Diosynth Biotechnologics

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type: Adenoviral Retroviral Adeno-Associated Others

By Application: Vaccinology Gene Therapy

By Disease:
Genetic Disorders
Infectious Diseases
Cancers
Others

By End-User:
Research institutes
Biopharmaceutical & Pharmaceutical Companies
Others

By Regions:





Target Audience of the Global Viral Vector Manufacturing Market in Market Study:



Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors



Contents

CHAPTER 1. EXECUTIVE SUMMARY

- 1.1. Market Snapshot
- 1.2. Key Trends
- 1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
- 1.3.1. Viral Vector Manufacturing Market, by Type, 2015-2025 (USD Billion)
- 1.3.2. Viral Vector Manufacturing Market, by Disease, 2015-2025 (USD Billion)
- 1.3.3. Viral Vector Manufacturing Market, by Application, 2015-2025 (USD Billion)
- 1.3.4. Viral Vector Manufacturing Market, by End-Use, 2015-2025 (USD Billion)
- 1.3.5. Viral Vector Manufacturing Market, by Region, 2015-2025 (USD Billion)
- 1.4. Estimation Methodology
- 1.5. Research Assumption

CHAPTER 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET DEFINITION AND SCOPE

- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
 - 2.2.1. Industry Evolution
 - 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates

CHAPTER 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET DYNAMICS

- 3.1. See Saw Analysis
 - 3.1.1. Market Drivers
 - 3.1.2. Market Challenges
 - 3.1.3. Market Opportunities

CHAPTER 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Buyers
 - 4.1.2. Bargaining Power of Suppliers
 - 4.1.3. Threat of New Entrants



- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.2. PEST Analysis
- 4.2.1. Political Scenario
- 4.2.2. Economic Scenario
- 4.2.3. Social Scenario
- 4.2.4. Technological Scenario
- 4.3. Key Buying Criteria
- 4.4. Regulatory Framework
- 4.5. Investment Vs Adoption Scenario
- 4.6. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY TYPE

- 5.1. Market Snapshot
- 5.2. Market Performance Potential Model
- 5.3. Viral Vector Manufacturing Market, Sub Segment Analysis
 - 5.3.1. Adenoviral
 - 5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.2. Retroviral
 - 5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.3. Adeno-Associated
 - 5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.4. Others
 - 5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY DISEASE

- 6.1. Market Snapshot
- 6.2. Market Performance Potential Model
- 6.3. Viral Vector Manufacturing Market, Sub Segment Analysis
 - 6.3.1. Genetic Disorders
 - 6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 6.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)



- 6.3.2. Infectious Diseases
 - 6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 6.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 6.3.3. Cancers
 - 6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 6.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 6.3.4. Others
- 6.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 6.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY APPLICATION

- 7.1. Market Snapshot
- 7.2. Market Performance Potential Model
- 7.3. Viral Vector Manufacturing Market, Sub Segment Analysis
 - 7.3.1. Vaccinology
 - 7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 7.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 7.3.2. Gene Therapy
 - 7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 7.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY END-USE

- 8.1. Market Snapshot
- 8.2. Market Performance Potential Model
- 8.3. Viral Vector Manufacturing Market, Sub Segment Analysis
 - 8.3.1. Research Institutes
 - 8.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 8.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 8.3.2. Biopharmaceutical & Pharmaceutical Companies
 - 8.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 8.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 8.3.3. Others
 - 8.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 8.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY



REGIONAL ANALYSIS

- 9.1. Viral Vector Manufacturing Market, Regional Market Snapshot (2015-2025)
- 9.2. North America Viral Vector Manufacturing Market Snapshot
 - 9.2.1. U.S.
 - 9.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.1.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.1.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.1.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.2. Canada
 - 9.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.2.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.2.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.2.2.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.3. Europe Viral Vector Manufacturing Market Snapshot
 - 9.3.1. U.K.
 - 9.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.1.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.1.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.1.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.2. Germany
 - 9.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.2.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.2.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.2.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.3. Rest of Europe
 - 9.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.3.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.3.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.3.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.3.3.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4. Asia Viral Vector Manufacturing Market Snapshot
 - 9.4.1. China
 - 9.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.4.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)



- 9.4.1.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.1.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.1.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.4.2. India

- 9.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.2.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.2.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.2.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.4.3. Japan

- 9.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.3.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.3.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.3.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.3.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.4.4. Rest of Asia Pacific

- 9.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.4.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.4.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.4.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.4.4.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.5. Latin America Viral Vector Manufacturing Market Snapshot

9.5.1. Brazil

- 9.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.1.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.1.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.1.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.5.2. Mexico

- 9.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.2.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.2.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.5.2.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

9.6. Rest of The World

9.6.1. South America

- 9.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
- 9.6.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.6.1.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)



- 9.6.1.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.6.1.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)
- 9.6.2. Middle East and Africa
 - 9.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
 - 9.6.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.6.2.3. Disease breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.6.2.4. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
 - 9.6.2.5. End-Use breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 10. COMPETITIVE INTELLIGENCE

- 10.1. Company Market Share (Subject to Data Availability)
- 10.2. Top Market Strategies
- 10.3. Company Profiles
 - 10.3.1. CGT Catapult
 - 10.3.1.1. Overview
 - 10.3.1.2. Financial (Subject to Data Availability)
 - 10.3.1.3. Product Summary
 - 10.3.1.4. Recent Developments
 - 10.3.2. Lonza
 - 10.3.3. Uniqure
 - 10.3.4. Merck
 - 10.3.5. Cobra Biologics
 - 10.3.6. Oxford BioMedica
 - 10.3.7. Novasep
 - 10.3.8. Spark Therapeutics

CHAPTER 11. RESEARCH PROCESS

- 11.1. Research Process
 - 11.1.1. Data Mining
 - 11.1.2. Analysis
 - 11.1.3. Market Estimation
 - 11.1.4. Validation
 - 11.1.5. Publishing
 - 11.1.6. Research Assumption



I would like to order

Product name: Global Viral Vector Manufacturing Market Size study, by Type (Adenoviral, Retroviral,

Adeno-Associated, others), by Application (Vaccinology, Gene Therapy), by Disease (Genetic Disorders, Infectious Diseases, Cancers, Others), End-User (Research Institutes, Biopharmaceutical & Pharmaceutical Companies, Others) and Regional

Forecasts 2018-2025

Product link: https://marketpublishers.com/r/G78D9F82E25EN.html

Price: US\$ 2,568.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G78D9F82E25EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$